Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study

Nature Communications

Volumn 6, Issue , 2015, Pages

  Chen, Pei Lung ^a,b,c   Shih, Shyang Rong ^a,b   Wang, Pei Wen ^d   Lin, Ying Chao ^e   Chu, Chen Chung ^f   Lin, Jung Hsin ^c,e,g   Chen, Szu Chi ^a,h   Chang, Ching Chung ^a,i,j   Huang, Tien Shang ^a,b,k   Tsai, Keh Sung ^a,b   Tseng, Fen Yu ^a   Wang, Chih Yuan ^a   Lu, Jin Ying ^a   Chiu, Wei Yih ^a   Chang, Chien Ching ^e   Chen, Yu Hsuan ^c   Chen, Yuan Tsong ^e,l   Fann, Cathy Shen Jang ^e   Yang, Wei Shiung ^a,b,c   Chang, Tien Chun ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f MACKAY MEMORIAL HOSPITAL   (Taiwan)

^g RESEARCH CENTER FOR APPLIED SCIENCES   (Taiwan)

^h TAIPEI CITY HOSPITAL   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^j CHINA MEDICAL UNIVERSITY   (Taiwan)

^k CATHAY GENERAL HOSPITAL   (Taiwan)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; HLA B ANTIGEN; HLA DRB1 ANTIGEN; PROPYLTHIOURACIL; THIAMAZOLE; THIONAMIDE; HLA ANTIGEN;

ABNORMALITY; ANTIGEN; CELLS AND CELL COMPONENTS; DRUG; GENE EXPRESSION; GENOMICS; GENOTYPE;

AGRANULOCYTOSIS; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG PROTEIN BINDING; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPING TECHNIQUE; GRAVES DISEASE; HLA TYPING; HUMAN; MALE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; CHEMICALLY INDUCED; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; ODDS RATIO;

AGRANULOCYTOSIS; ANTITHYROID AGENTS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HLA ANTIGENS; HLA-B ANTIGENS; HLA-DRB1 CHAINS; HUMANS; ODDS RATIO;

EID: 84936760867     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8633     Document Type: Article

References (52)

1. Weetman, A. P. Graves' disease. N. Engl. J. Med. 343, 1236-1248 (2000).
2. Tunbridge, W. M. et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin. Endocrinol. (Oxf.) 7, 481-493 (1977).
3. Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84, 223-243 (1997).
4. Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905-917 (2005).
5. Tajiri, J. & Noguchi, S. Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid 14, 459-462 (2004).
6. Nakamura, H., Miyauchi, A., Miyawaki, N. & Imagawa, J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J. Clin. Endocrinol. Metab. 98, 4776-4783 (2013).
7. Andersohn, F., Konzen, C. & Garbe, E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann. Intern. Med. 146, 657-665 (2007).
8. Huber, M. et al. Drug-induced agranulocytosis in the Berlin case-control surveillance study. Eur. J. Clin. Pharmacol. 70, 339-345 (2014).
9. Edwards, I. R. & Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356, 1255-1259 (2000).
10. Aronson, J. K. & Ferner, R. E. Joining the DoTS: new approach to classifying adverse drug reactions. Br. Med. J. 327, 1222-1225 (2003).
11. Wang, L., McLeod, H. L. & Weinshilboum, R. M. Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011).
12. Yunis, J. J. et al. HLA associations in clozapine-induced agranulocytosis. Blood 86, 1177-1183 (1995).
13. Tamai, H. et al. Association between the DRB1∗08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann. Intern. Med. 124, 490-494 (1996).
14. Valevski, A. et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur. J. Immunogenet. 25, 11-13 (1998).
15. Opgen-Rhein, C. & Dettling, M. Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 9, 1101-1111 (2008).
16. Zhang, J. P. & Malhotra, A. K. Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin. Drug Metab. Toxicol. 9, 183-191 (2013).
17. Chung, W. H. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
18. Ozeki, T. et al. Genome-wide association study identifies HLA-A∗3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20, 1034-1041 (2011).
19. Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
20. Mallal, S. et al. Association between presence of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
21. Spraggs, C. F. et al. HLA-DQA1∗02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 29, 667-673 (2011).
22. Chen, P. L. et al. Comprehensive genotyping in two homogeneous Graves' disease samples reveals major and novel HLA association alleles. PLoS ONE 6, e16635 (2011).
23. Pavlos, R., Mallal, S. & Phillips, E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 13, 1285-1306 (2012).
24. Klein, J. & Sato, A. The HLA system. First of two parts. N. Engl. J. Med. 343, 702-709 (2000).
25. Lucena, M. I. et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141, 338-347 (2011).
26. Erlich, H. A., Opelz, G. & Hansen, J. HLA DNA typing and transplantation. Immunity 14, 347-356 (2001).
27. Gonzalez-Galarza, F. F., Christmas, S., Middleton, D. & Jones, A. R. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39, D913-D919 (2011).
28. Lieberman, J. A. et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch. Gen. Psychiatry 47, 945-948 (1990).
29. DeLuca, D. S. & Blasczyk, R. HistoCheck. Evaluating structural and functional MHC similarities. Methods Mol. Biol. 409, 395-405 (2007).
30. Huang, C. H., Li, K. L., Wu, J. H., Wang, P. N. & Juang, J. H. Antithyroid drug-induced agranulocytosis: report of 13 cases. Chang Gung Med. J. 30, 242-248 (2007).
31. Sheng, W. H. et al. Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections. QJM 92, 455-461 (1999).
32. Noble, J. A. & Valdes, A. M. Genetics of the HLA region in the prediction of type 1 diabetes. Curr. Diab. Rep. 11, 533-542 (2011).
33. Pociot, F. & McDermott, M. F. Genetics of type 1 diabetes mellitus. Genes Immun. 3, 235-249 (2002).
34. Okada, Y. et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum. Mol. Genet. 23, 6916-6926 (2014).
35. Zaki, S. A. Adverse drug reaction and causality assessment scales. Lung India 28, 152-153 (2011).
36. Naranjo, C. A. et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 30, 239-245 (1981).
37. Gauderman, W. J. Sample size requirements for association studies of gene-gene interaction. Am. J. Epidemiol. 155, 478-484 (2002).
38. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76-82 (2011).
39. Chu, X. et al. A genome-wide association study identifies two new risk loci for Graves' disease. Nat. Genet. 43, 897-901 (2011).
40. Jia, X. et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS ONE 8, e64683 (2013).
41. Pillai, N. E. et al. Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations. Hum. Mol. Genet. 23, 4443-4451 (2014).
42. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725-738 (2010).
43. Eswar, N. et al. Comparative protein structure modeling using Modeller. Curr. Protoc. Bioinformatics Chapter 5, Unit 5-Unit 6 (2006).
44. Li, H., Robertson, A. D. & Jensen, J. H. Very fast empirical prediction and rationalization of protein pK(a) values. Proteins 61, 704-721 (2005).
45. Dolinsky, T. J., Nielsen, J. E., McCammon, J. A. & Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665-W667 (2004).
46. Hehre, W. J., Ditchfie, R. & Pople, J. A. Self-consistent molecular-orbital methods.12. Further extensions of Gaussian-type basis sets for use in molecular-orbital studies of organic-molecules. J. Chem. Phys. 56, 2257-2261 (1972).
47. Bayly, C. I., Cieplak, P., Cornell, W. D. & Kollman, P. A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges - the resp model. J. Phys. Chem. 97, 10269-10280 (1993).
48. Morris, G. M. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791 (2009).
49. Wang, J. C., Lin, J. H., Chen, C. M., Perryman, A. L. & Olson, A. J. Robust scoring functions for protein-ligand interactions with quantum chemical charge models. J. Chem. Inf. Model. 51, 2528-2537 (2011).
50. Hornak, V. et al. Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725 (2006).
51. Wang, J. M., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157-1174 (2004).
52. Pettersen, E. F. et al. UCSF chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).